Publications by authors named "Kendra Avery"

T-cell activation is a multistep process requiring T-cell receptor engagement by peptide-major histocompatibility complexes (Signal 1) coupled with CD28-mediated costimulation (Signal 2). Tumors typically lack expression of CD28 ligands, so tumor-specific Signal 1 (e.g.

View Article and Find Full Text PDF

Introduction: Interleukin 15 (IL-15) is a potential anticancer agent and numerous engineered IL-15 agonists are currently under clinical investigation. Selective targeting of IL-15 to specific lymphocytes may enhance therapeutic effects while helping to minimize toxicities.

Methods: We designed and built a heterodimeric targeted cytokine (TaCk) that consists of an anti-programmed cell death 1 receptor antibody (anti-PD-1) and an engineered IL-15.

View Article and Find Full Text PDF

An insufficient quantity of functional T cells is a likely factor limiting the clinical activity of T-cell bispecific antibodies, especially in solid tumor indications. We hypothesized that XmAb24306 (efbalropendekin alfa), a lymphoproliferative interleukin (IL)-15/IL-15 receptor α (IL-15Rα) Fc-fusion protein, may potentiate the activity of T-cell dependent (TDB) antibodies. The activation of human peripheral T cells by cevostamab, an anti-FcRH5/CD3 TDB, or anti-HER2/CD3 TDB resulted in the upregulation of the IL-2/15Rβ (CD122) receptor subunit in nearly all CD8+ and majority of CD4+ T cells, suggesting that TDB treatment may sensitize T cells to IL-15.

View Article and Find Full Text PDF

Introduction: The progression-free survival of patients with HER2-positive metastatic breast cancer is significantly extended by a combination of two monoclonal antibodies, trastuzumab and pertuzumab, which target independent epitopes of the extracellular domain of HER2. The improved efficacy of the combination over individual antibody therapies targeting HER2 is still being investigated, and several molecular mechanisms may be in play: the combination downregulates HER2, improves antibody-dependent cell mediated cytotoxicity, and/or affects the organization of surface-expressed antigens, which may attenuate downstream signaling.

Methods: By combining protein engineering and quantitative single molecule localization microscopy (qSMLM), here we both assessed and optimized clustering of HER2 in cultured breast cancer cells.

View Article and Find Full Text PDF
Article Synopsis
  • Quantitative single molecule localization microscopy (qSMLM) has been enhanced by a new method called surface assay for molecular isolation (SAMI), which helps accurately analyze protein organization.
  • The study addressed challenges in detecting proteins due to variability in fluorescent labels and reporter size by using engineered antibody fragments with specific fluorescent ligands.
  • By applying SAMI-qSMLM, researchers were able to investigate differences in the density and arrangement of epidermal growth factor receptors in breast cancer cells after treatment with various drugs, which can lead to new insights in cancer research.
View Article and Find Full Text PDF
Article Synopsis
  • Monoclonal antibodies (mAbs) are highly specific and effective, leading to efforts to enhance their function with various therapeutic agents for better treatment outcomes and diagnostic purposes.
  • Researchers discovered a new interaction called meditope-Fab that significantly improves the binding affinity and stability of mAbs, increasing their effectiveness.
  • By creating a mechanical bond using click chemistry, these enhanced mAbs can retain their specific targeting ability while also being used for tumor imaging in mice, suggesting potential for rapid development of new mAb combinations for therapy and diagnostics.
View Article and Find Full Text PDF

Meditope, a cyclic 12-residue peptide, binds to a unique binding side between the light and heavy chains of the cetuximab Fab. In an effort to improve the affinity of the interaction, it was sought to extend the side chain of Arg8 in the meditope, a residue that is accessible from the other side of the meditope binding site, in order to increase the number of interactions. These modifications included an n-butyl and n-octyl extension as well as hydroxyl, amine and carboxyl substitutions.

View Article and Find Full Text PDF

We have previously identified a cyclic peptide called meditope which binds to the central cavity of the Fab portion of cetuximab and shown that this peptide binding site can be grafted, or 'meditope-enabled', onto trastuzumab. This peptide has been shown to act as a hitch for the non-covalent attachment of imaging agents to meditope-enabled antibodies. Herein, we explore the process of grafting this peptide binding site onto M5A, an anti-CEA antibody in clinical trials for cancer diagnostics.

View Article and Find Full Text PDF
Article Synopsis
  • Multiple crystal structures of meditope peptide derivatives, featuring both natural and unnatural amino acids, were analyzed in their binding to the cetuximab Fab domain.
  • The study utilized surface plasmon resonance to measure how these substitutions affected binding affinity, revealing that certain hydrophobic changes lowered overall affinity and interaction stability.
  • Notably, substitutions like Phe3 with diphenylalanine improved half-life, while changes to Leu5 and Arg8/Arg9 further decreased affinity, highlighting critical amino acid roles in the meditope-cetuximab interaction.
View Article and Find Full Text PDF
Article Synopsis
  • A novel binding site for a cyclic 12-residue peptide was found within the cetuximab Fab domain, prompting research into how variations in the peptide and antibody affect their interactions.
  • Multiple crystal structures of different cyclic peptides were analyzed, revealing that specific modifications, like amidation and acetylation, enhanced binding affinity, while converting the peptide to a linear form drastically weakened it.
  • The study concluded that minor changes in the peptide's cyclization can substantially influence the strength of its interaction with the Fab domain, highlighting the importance of structural details in peptide-antibody complexes.
View Article and Find Full Text PDF

Functionalization of monoclonal antibodies (mAbs) requires chemical derivatization and/or genetic manipulation. Inherent in these methods are challenges with protein heterogeneity, stability and solubility. Such perturbations could potentially be avoided by using a high affinity, non-covalent intermediate to bridge the desired functionality to a stable mAb.

View Article and Find Full Text PDF

Lymphomas arising from NK or γδ-T cells are very aggressive diseases and little is known regarding their pathogenesis. Here we report frequent activating mutations of STAT3 and STAT5B in NK/T-cell lymphomas (n=51), γδ-T-cell lymphomas (n=43) and their cell lines (n=9) through next generation and/or Sanger sequencing. STAT5B N642H is particularly frequent in all forms of γδ-T-cell lymphomas.

View Article and Find Full Text PDF

Capitalizing on their extraordinary specificity, monoclonal antibodies (mAbs) have become one of the most reengineered classes of biological molecules. A major goal in many of these engineering efforts is to add new functionality to the parental mAb, including the addition of cytotoxins and imaging agents for medical applications. Herein, we present a unique peptide-binding site within the central cavity of the fragment antigen binding framework region of the chimeric, anti-epidermal growth factor receptor mAb cetuximab.

View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Notice

Message: fwrite(): Write of 34 bytes failed with errno=28 No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 272

Backtrace:

A PHP Error was encountered

Severity: Warning

Message: session_write_close(): Failed to write session data using user defined save handler. (session.save_path: /var/lib/php/sessions)

Filename: Unknown

Line Number: 0

Backtrace: